GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Konruns Pharmaceutical Co Ltd (SHSE:603590) » Definitions » Shares Outstanding (EOP)
中文

Beijing Konruns Pharmaceutical Co (SHSE:603590) Shares Outstanding (EOP) : 160.0 Mil (As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Beijing Konruns Pharmaceutical Co Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Beijing Konruns Pharmaceutical Co's shares outstanding for the quarter that ended in Sep. 2023 was 160.0 Mil.

Beijing Konruns Pharmaceutical Co's quarterly shares outstanding stayed the same from Jun. 2023 (160.0 Mil) to Sep. 2023 (160.0 Mil).

Beijing Konruns Pharmaceutical Co's annual shares outstanding stayed the same from Dec. 2021 (160.0 Mil) to Dec. 2022 (160.0 Mil).


Beijing Konruns Pharmaceutical Co Shares Outstanding (EOP) Historical Data

The historical data trend for Beijing Konruns Pharmaceutical Co's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Konruns Pharmaceutical Co Shares Outstanding (EOP) Chart

Beijing Konruns Pharmaceutical Co Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 160.00 160.00 160.00 160.00 160.00

Beijing Konruns Pharmaceutical Co Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 160.00 160.00 160.00 160.00 160.00

Competitive Comparison of Beijing Konruns Pharmaceutical Co's Shares Outstanding (EOP)

For the Biotechnology subindustry, Beijing Konruns Pharmaceutical Co's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Konruns Pharmaceutical Co's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Konruns Pharmaceutical Co's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Beijing Konruns Pharmaceutical Co's Shares Outstanding (EOP) falls into.



Beijing Konruns Pharmaceutical Co Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Beijing Konruns Pharmaceutical Co  (SHSE:603590) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Beijing Konruns Pharmaceutical Co Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Beijing Konruns Pharmaceutical Co's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Konruns Pharmaceutical Co (SHSE:603590) Business Description

Traded in Other Exchanges
N/A
Address
No. 11 Xingsheng South Road, Economic Development Zone, Miyun District, Beijing, CHN
Beijing Konruns Pharmaceutical Co Ltd is a Chinese pharmaceutical company. It is engaged in the research and development of innovative drugs, and is oriented to clinical needs.

Beijing Konruns Pharmaceutical Co (SHSE:603590) Headlines

No Headlines